BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of $13.69 million. The enterprise value is -$438,619.
Important Dates
The last earnings date was Monday, November 24, 2025, before market open.
| Earnings Date | Nov 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.61 billion shares outstanding. The number of shares has increased by 86.44% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.61B |
| Shares Change (YoY) | +86.44% |
| Shares Change (QoQ) | +10.02% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 3.50% |
| Float | 2.50B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.08 |
| Forward PS | n/a |
| PB Ratio | 0.70 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09, with a Debt / Equity ratio of 0.58.
| Current Ratio | 2.09 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.85 |
Financial Efficiency
Return on equity (ROE) is -21.24% and return on invested capital (ROIC) is -18.24%.
| Return on Equity (ROE) | -21.24% |
| Return on Assets (ROA) | -13.60% |
| Return on Invested Capital (ROIC) | -18.24% |
| Return on Capital Employed (ROCE) | -38.53% |
| Revenue Per Employee | $454,821 |
| Profits Per Employee | -$106,321 |
| Employee Count | 28 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 2.19 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.23% in the last 52 weeks. The beta is 0.58, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -70.23% |
| 50-Day Moving Average | 3.62 |
| 200-Day Moving Average | 3.72 |
| Relative Strength Index (RSI) | 43.68 |
| Average Volume (20 Days) | 26,896 |
Short Selling Information
| Short Interest | 180,688 |
| Short Previous Month | 188,036 |
| Short % of Shares Out | 4.42% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.15 |
Income Statement
In the last 12 months, BioLineRx had revenue of $12.74 million and -$2.98 million in losses. Loss per share was -$0.00.
| Revenue | 12.74M |
| Gross Profit | 6.46M |
| Operating Income | -10.07M |
| Pretax Income | -2.98M |
| Net Income | -2.98M |
| EBITDA | -8.37M |
| EBIT | -10.07M |
| Loss Per Share | -$0.00 |
Full Income StatementBalance Sheet
The company has $25.21 million in cash and $11.38 million in debt, giving a net cash position of $13.83 million or $0.01 per share.
| Cash & Cash Equivalents | 25.21M |
| Total Debt | 11.38M |
| Net Cash | 13.83M |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 19.53M |
| Book Value Per Share | 0.01 |
| Working Capital | 14.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.48 million and capital expenditures $6,000, giving a free cash flow of -$13.48 million.
| Operating Cash Flow | -13.48M |
| Capital Expenditures | 6,000 |
| Free Cash Flow | -13.48M |
| FCF Per Share | -$0.01 |
Full Cash Flow StatementMargins
Gross margin is 50.69%, with operating and profit margins of -79.08% and -23.38%.
| Gross Margin | 50.69% |
| Operating Margin | -79.08% |
| Pretax Margin | -23.38% |
| Profit Margin | -23.38% |
| EBITDA Margin | -65.73% |
| EBIT Margin | -79.08% |
| FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -86.44% |
| Shareholder Yield | n/a |
| Earnings Yield | -21.74% |
| FCF Yield | -98.44% |
Analyst Forecast
The average price target for BioLineRx is $19.00, which is 463.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.00 |
| Price Target Difference | 463.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 30, 2025. It was a reverse split with a ratio of 1:40.
| Last Split Date | Jan 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
BioLineRx has an Altman Z-Score of -13.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.52 |
| Piotroski F-Score | 2 |
